Search results for "emot"

showing 10 items of 5695 documents

Adjuvant Intravesical Chemotherapy in Patients with Primary T1 G3 Transitional Cell Carcinoma of the Bladder

1993

The Authors present their experience with TUR plus adjuvant intravesical chemotherapy in 50 patients affected by primary T1 G3 bladder tumours without previous or concomitant carcinoma in situ. At a mean follow-up of 36 months, 84% of the patients are alive and tumour-free. Cystectomy was performed in three patients due to locally invasive disease. Five patients (10%) died of bladder cancer.

medicine.medical_specialtybusiness.industryCarcinoma in situmedicine.medical_treatmentUrologyGeneral Medicinemedicine.diseaseTransitional cell carcinomaConcomitantMedicineIn patientbusinessIntravesical chemotherapyAdjuvantUrologia Journal
researchProduct

P2482Prediction of in-hospital cardiogenic shock development among patients with ST-segment elevation myocardial infarction treated by primary percut…

2018

medicine.medical_specialtybusiness.industryCardiogenic shockmedicine.medical_treatmentPercutaneous coronary interventionmedicine.diseaseElevation (emotion)Internal medicineCardiologyMedicineST segmentMyocardial infarctionCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Emotional status and fear in patients scheduled for elective surgery during COVID-19 pandemic: a nationwide cross-sectional survey (COVID-SURGERY)

2021

Abstract Background Fragmented data exist on the emotional and psychological distress generated by hospital admission during the pandemic in specific populations of patients, and no data exists on patients scheduled for surgery. The aim of this multicentre nationwide prospective cross-sectional survey was to evaluate the impact of pandemic on emotional status and fear of SARS-CoV-2 contagion in a cohort of elective surgical patients in Italy, scheduled for surgery during the COVID-19 pandemic. Results Twenty-nine Italian centres were involved in the study, for a total of 2376 patients surveyed (mean age of 58 years ± 16.61; 49.6% males). The survey consisted of 28 total closed questions, in…

medicine.medical_specialtybusiness.industryCross-sectional studyEmotional statusCOVID-19 Perioperative medicine Emotional status SurveyCOVID-19PerioperativeDiseaseSurgeryPerioperative medicineAnesthesiologyCohortPandemicMedicineOriginal ArticleGeneral anaesthesiaElective surgerySurveybusinessJournal of Anesthesia, Analgesia and Critical Care
researchProduct

Baseline patient characteristics of the German multicentric prospective real-world NAFLD cohort: The Fatty Liver Assessment in Germany (FLAG) study

2019

medicine.medical_specialtybusiness.industryFatty liverPatient characteristicsmedicine.diseaselanguage.human_languageGermanInternal medicineCohortlanguagemedicineFLAG (chemotherapy)Baseline (configuration management)business35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
researchProduct

Chirurgische Therapie von Lebermetastasen kolorektaler Karzinome

2003

Resection is the only curative treatment of colorectal liver metastases proofed by a long-term follow-up. The operation is indicated if the metastases are completely removable with sufficient liver parenchyma remaining after resection and if the patient is fit for surgery. The resection is not indicated in cases with non resectable extrahepatic tumours and lymph node metastases distal the hepatoduodenal ligament. The postoperative mortality amounts to about 5 % and the 5-year-survival-rates range between 20 and 40 % depending on the selection of patients. Aims of new concepts of operative therapy are the improvement of resectability by preoperative portal vein embolization, the resection co…

medicine.medical_specialtybusiness.industryHepatoduodenal ligamentSurgeryResectionmedicine.anatomical_structurePortal vein embolizationmedicinePreoperative chemotherapySurgeryOperative therapySurgical treatmentbusinessLymph nodeLiver parenchymaZentralblatt für Chirurgie
researchProduct

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Rando…

2012

Abstract Abstract 412 Background: A large proportion of patients are currently not eligible for genotype-adapted strategies in acute myeloid leukemia (AML), in particular those lacking specific genetic aberrations such as PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, NPM1 or activating FLT3 mutations. This subgroup of patients accounts for about one-third of all AML patients and mainly includes the large group of AML with myelodysplasia-related changes, AML with recurrent cytogenetic abnormalities [inv(3) or t(3;3), t(9;11), t(v;11q23)] and cytogenetically normal AML (CN-AML) with wild-type NPM1 and FLT3. Prognosis in this subgroup of patients is generally poor. Azacitidine has been shown to be acti…

medicine.medical_specialtybusiness.industryImmunologyAzacitidineInduction chemotherapyCell BiologyHematologyGene mutationBiochemistryGastroenterology3. Good healthSurgeryTransplantation03 medical and health sciences0302 clinical medicineMaintenance therapy030220 oncology & carcinogenesisInternal medicinemedicineCytarabineIdarubicinbusinessEtoposide030215 immunologymedicine.drugBlood
researchProduct

Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study

2013

Abstract Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII:C). Immunosuppressive treatment may result in remission of disease over a period of days to months. Until remission, patients are at high risk of bleeding and complications from immunosuppression. Prognostic parameters to predict remission and the time needed to achieve remission could be helpful to guide treatment intensity, but have not been established so far. GTH-AH01/2010 was a prospective multicenter cohort study using a standardized immunosuppressive treatment protocol. The primary study endpoint was time to achieve partial remission (PR, def…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionCell BiologyHematologyOff-label useBiochemistryHemophiliasInterquartile rangeInternal medicineImmunologyAcquired hemophiliamedicineHemotherapyRituximabbusinessCohort studymedicine.drugBlood
researchProduct

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial …

2008

Abstract We have previously reported that compared to CHOP alone the addition of Rituximab (R) to CHOP significantly increases the response rate (RR), the time to treatment failure (TTF) and also the overall survival (OS) in patients with newly diagnosed advanced follicular lymphoma. However, in the previous report, the median observation time was short with 18 months and no data were reported on the outcome of different risk groups according to the FLIPI (Hiddemann et al., Blood 2005). We now report on the treatment outcome of 552 patients with advanced stage follicular lymphoma randomized between R-CHOP versus CHOP alone after a median follow up of 58 months. Responding patients < …

medicine.medical_specialtybusiness.industryImmunologyFollicular lymphomaAlpha interferonCell BiologyHematologyCHOPDebulkingmedicine.diseaseBiochemistryChemotherapy regimenGastroenterologySurgerylaw.inventionRandomized controlled trialMedian follow-uplawInternal medicinemedicineRituximabbusinessmedicine.drugBlood
researchProduct

Absorption of drugs from the bladder and intravesical chemotherapy

1976

medicine.medical_specialtybusiness.industryUrologyUrinary BladderUrologyAntineoplastic AgentsPharmaceutical PreparationsUrinary Bladder NeoplasmsInjections IntravenousAnimalsHumansMedicineRabbitsIntravesical chemotherapybusinessAbsorption (electromagnetic radiation)ThiotepaUrological Research
researchProduct

The immune response behavior in HIV-AIDS patients treated with ozone therapy for two years

2018

HIV continues to be one of the biggest problems for the global public health. The African region is one of the most affected, accounting for almost two thirds of the new infections. Many of them are retroviral medications and multi-therapies aiming to stop the viral replication and maintaining immunological stability, which fail to guarantee the quality of life or enhance the patient's immunity
 Ozone has biological properties, among which the antimicrobial and modulatory effect on the immune response is highlighted, which makes it possible to use it in a complementary way for the treatment of these patients.
 We conducted the present study in which the effect of the ozone therapy…

medicine.medical_specialtybusiness.industrymedicine.diseaseOzone therapyAntimicrobial:CIENCIAS MÉDICAS [UNESCO]AutohemotherapyImmune systemAcquired immunodeficiency syndrome (AIDS)ImmunityInternal medicineUNESCO::CIENCIAS MÉDICASmedicinebusinessViral loadCD8
researchProduct